SCHEMBL333675

SCHEMBL333675

NONCC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23829690 0.71
SCHEMBL7055838 0.71
SCHEMBL2701192 0.71
SCHEMBL16436873 0.71
SCHEMBL24439848 0.69
SCHEMBL27697046 0.67
SCHEMBL7168792 0.67
SCHEMBL23761696 0.67
SCHEMBL10557403 0.67
SCHEMBL1758271 0.65 EGLN1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595314-B2 Antibody specific for GPC3 and methods of use thereof R.P. SCHERER TECHNOLOGIES, LLC (US) 2026-04-07 US disclosed
US-20250084182-A1 ANTIBODY SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF ARES CAPITAL CORPORATION, AS COLLATERAL AGENT 2025-03-13 US disclosed
US-12116409-B2 Antibody specific for CD22 and methods of use thereof REDWOOD BIOSCIENCE, INC. (US) 2024-10-15 US disclosed
US-11970546-B2 Antibody specific for Mucin-1 and methods of use thereof R.P. SCHERER TECHNOLOGIES, LLC (US) 2024-04-30 US disclosed
CN-116322770-A Antibodies specific for mucin-1 and methods of use thereof R·P·舍勒科技有限责任公司 2023-06-23 CN disclosed
EP-4188432-A1 ANTIBODY SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF R.P. Scherer Technologies, LLC (US) 2023-06-07 EP disclosed
US-20220251237-A1 Antibody Specific for GPC3 and Methods of Use Thereof ARES CAPITAL CORPORATION, AS COLLATERAL AGENT 2022-08-11 US disclosed
US-20220220198-A1 ANTIBODY SPECIFIC FOR CD22 AND METHODS OF USE THEREOF ARES CAPITAL CORPORATION, AS COLLATERAL AGENT 2022-07-14 US disclosed
EP-4007604-A1 ANTIBODY SPECIFIC FOR GPC3 AND METHODS OF USE THEREOF R.P. Scherer Technologies, LLC (US) 2022-06-08 EP disclosed
CN-114340671-A Antibodies specific for GPC3 and methods of use thereof R.P.谢勒技术有限责任公司 2022-04-12 CN disclosed
US-20110287041-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-11-24 US disclosed
US-20110250704-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-10-13 US disclosed
US-7985783-B2 Aldehyde tags, uses thereof in site-specific protein modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-07-26 US disclosed
US-20110117621-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-05-19 US disclosed
US-20110111443-A1 APPARATUS FOR AUTO-PRETREATING SUGAR CHAIN NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2011-05-12 US disclosed
EP-2207030-A1 APPARATUS FOR AUTO-PRETREATING SUGAR CHAIN Hokkaido University (JP) 2010-07-14 EP disclosed
WO-2009120611-A2 ALDEHYDE TAGS, USES THEREOF IN SITE-SPECIFIC PROTEIN MODIFICATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-10-01 WO disclosed
EP-2064334-A2 ALDEHYDE TAGS, USES THEREOF IN SITE-SPECIFIC PROTEIN MODIFICATION The Regents of the University of California (US) 2009-06-03 EP disclosed
US-20080187956-A1 Modification at sulfatase motif of aldehyde tag through action of a formylglycine generating enzyme (FGE) generates formylglycine (FGly) residue NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-08-07 US disclosed
WO-2008036350-A2 ALDEHYDE TAGS, USES THEREOF IN SITE-SPECIFIC PROTEIN MODIFICATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-27 WO disclosed